Ginkgo Bioworks (DNA) Reports In-Line Q2 EPS; Offers FY23 Revenue Guidance

Ginkgo Bioworks (NYSE: DNA) reported Q2 EPS of ($0.09), in-line with the analyst estimate of ($0.09). Revenue for the quarter came in at $80.6 million versus the consensus estimate of $71.5 million.

GUIDANCE:

Ginkgo Bioworks sees FY2023 revenue of $245-260 million, versus the consensus of $292.8 million.

For earnings history and earnings-related data on Ginkgo Bioworks (DNA) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Cloudastructure restructures preferred stock, issues $1.3M promissory note
• Vertex to acquire Crinetics Pharmaceuticals for $10 billion